Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 31383016)

  • 1. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
    Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
    J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.
    Sui M; Li Y; Wang H; Luo Y; Wan T; Wang X; Hu B; Cheng Y; Lv X; Xin X; Xu Q; Wang G; Lu S
    J Immunother Cancer; 2019 May; 7(1):125. PubMed ID: 31064408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
    Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H
    BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: The MSI-L/p-MMR metastatic rectal cancer patient who failed systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy.
    Liu S; Zhang Y; Lin Y; Wang P; Pan Y
    Front Immunol; 2022; 13():981527. PubMed ID: 36119063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rectosigmoid-Junction Squamous Cell Carcinoma With pMMR/MSS Achieved a Partial Response Following PD-1 Blockade Combined With Chemotherapy: A Case Report.
    He Y; Wang L; Li X; Zhang T; Song T; Zhang J; Yu Y; Chen S; Song H
    Front Oncol; 2021; 11():596342. PubMed ID: 34113555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report.
    Zhang F; Zhang J; Zhao L; Zhai M; Zhang T; Yu D
    Front Immunol; 2021; 12():759250. PubMed ID: 34950137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review.
    Liao CX; Deng CS; Liang X; Yang JC; Chen ZZ; Lin XY; Lin CF; Chen S; Wu SS
    Front Immunol; 2023; 14():1239168. PubMed ID: 37753076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent Gallbladder Carcinoma With pMMR/MSS Achieved a Complete Response Following Camrelizumab Combined With Apatinib: A Case Report.
    Zhong L; Liu X; Li Z; Zhang X; Wang Y; Peng W
    Front Oncol; 2021; 11():783158. PubMed ID: 35096582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.
    Mou H; Yu L; Liao Q; Hou X; Wu Y; Cui Q; Yan N; Ma R; Wang L; Yao M; Wang K
    BMC Cancer; 2018 Nov; 18(1):1105. PubMed ID: 30419854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.
    Zhang Z; Zhang W; Wang H; Hu B; Wang Z; Lu S
    Front Immunol; 2021; 12():744571. PubMed ID: 34603331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report: Genetic and immune microenvironmental characteristics of a rectal cancer patient with MSS/PD-L1-negative recurrent hepatopulmonary metastasis who achieved complete remission after treatment with PD-1 inhibitor.
    Song Y; Long J; Su X; Chen Z; He Y; Shao W; Wang B; Chen C
    Front Immunol; 2023; 14():1197543. PubMed ID: 37520536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report.
    Liu Y; Du J; Zhang P; Meng W; Xiao H
    Front Oncol; 2023; 13():1051786. PubMed ID: 36969074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer.
    Pei F; He W; Duan Y; Yao Q; Zhao Y; Fan X; Liu S; Chen H; He F; Liu T; Chen J; Zheng Y; Li H; Guo X; Shi L; Ling L; Chen Y; He J; Liu M; Huang M; Bai Y; Wang J; Huang M; Huang J
    Cancer Med; 2024 Jun; 13(12):e7224. PubMed ID: 38888366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
    Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
    Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report.
    Yang J; Xing P; Kong Y; Xu M; Zhang L
    Front Oncol; 2023; 13():1078915. PubMed ID: 37188188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
    Dong Z; Liao B; Shen W; Sui C; Yang J
    Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.